Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia Clinical research trials and A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia. A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia clinical trial. Human subjects often get the best healthcare possible for their A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.

Home > "A" Clinical Trials Conditions > A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia

A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia



A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia

For Condition: HIV Infections,Cytopenias
Status: Completed
Sponsor(s): Sandoz Pharmaceuticals ,
Synopsis: To determine the maximum tolerated dose (MTD) and toxicity of sargramostim (recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF) given by continuous intravenous infusion (CIV) in patients with leukopenia in association with AIDS virus infection. In addition, single dose and steady state pharmacokinetics will also be determined.
Details:
Eligibility:
Study Type:
  Interventional, Treatment, Dose Comparison, Pharmacokinetics Study
Minimum Age/Maximum Age: 18 Years/50 Years
Genders: Male
Protocol Entry Criteria: Inclusion Criteria Patients must have: - Met the CDC criteria for the diagnosis of AIDS. - Total peripheral blood leukocyte count = or < 3000 cells/mm3 measured on at least two occasions separated by a minimum of one week. - Must have or have recovered from one or more opportunistic infection. - Serum antibody to HTLV-III/LAV with or without viremia. - Anticipated survival of at least 6 months. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - AIDS related complex (ARC). - History of malignancy other than Kaposi's sarcoma (KS). - Excessive diarrhea (more than 5 liquid or non-liquid stools per day). - Currently hospitalized or hospitalized within the last 4 weeks for the treatment of opportunistic infections. - Presence of renal dysfunction. - Other evidence of primary hematologic or infectious disorders unrelated to AIDS virus infection. Patients with the following are excluded: - AIDS related complex (ARC). - History of malignancy other than Kaposi's sarcoma (KS). - Excessive diarrhea (more than 5 liquid or non-liquid stools per day). - Currently hospitalized or hospitalized within the last 4 weeks for the treatment of an opportunistic infection. - Dementia or altered mental status that would prohibit the giving and understanding of informed consent. Prior Medication: Excluded: - Any marrow suppressive medications such as trimethoprim-sulfamethoxazole combination (TMP-PurposeX) or Fansidar. - Excluded within 6 weeks of study entry: - Any investigational drug. Prior Treatment: Excluded within 6 weeks of study entry: - Systemic cytotoxic chemotherapy or irradiation. Risk Behavior: Excluded within 3 months of study entry: - Regular, excessive use of alcohol, hallucinogens or agents which are addicting.
Total Enrollment: 

Location and Contact Information:

Beth Israel Deaconess - West Campus
Boston,  Massachusetts,  02215
United States
 

UCLA CARE Ctr
Los Angeles,  California,  90095
United States
 


Additional Information:
Study ID Numbers:
  067E;  101
Study Start Date: 
Record last reviewed: June 1988
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002009

Other Hiv Infections Studies:
1. An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients with AIDS Virus Infection and Leukopenia

2. A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia

3. A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients with AIDS or AIDS-Related Complex

4. A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia

5. The Safety and Effectiveness of r-HuEPO in Patients with AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic

Related Studies:

Other HIV Infections Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials

A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia

Modify your Search

  Other HIV Infections Clinical Trials
  Other Massachusetts Clinical Trials
  Other Boston Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103